TY - JOUR
T1 - Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
AU - Duffy, David J.
AU - Krstic, Aleksandar
AU - Halász, Melinda
AU - Schwarzl, Thomas
AU - Fey, Dirk
AU - Iljin, Kristiina
AU - Mehta, Jai Prakash Rakash
AU - Killick, Kate E.
AU - Whilde, Jenny
AU - Turriziani, Benedetta
AU - Haapa-Paananen, Saija
AU - Fey, Vidal
AU - et al., null
PY - 2015
Y1 - 2015
N2 - Despite intensive study, many mysteries remain about the
MYCN oncogene's functions. Here we focus on MYCN's role
in neuroblastoma, the most common extracranial childhood
cancer. MYCN gene amplification occurs in 20% of cases,
but other recurrent somatic mutations are rare. This
scarcity of tractable targets has hampered efforts to
develop new therapeutic options. We employed a multilevel
omics approach to examine MYCN functioning and identify
novel therapeutic targets for this largely un-druggable
oncogene. We used systems medicine based computational
network reconstruction and analysis to integrate a range
of omic techniques: Sequencing-based transcriptomics,
genome-wide chromatin immunoprecipitation, siRNA
screening and interaction proteomics, revealing that MYCN
controls highly connected networks, with MYCN primarily
supressing the activity of network components. MYCN's
oncogenic functions are likely independent of its
classical heterodimerisation partner, MAX. In particular,
MYCN controls its own protein interaction network by
transcriptionally regulating its binding partners. Our
network-based approach identified vulnerable
therapeutically targetable nodes that function as
critical regulators or effectors of MYCN in
neuroblastoma. These were validated by siRNA knockdown
screens, functional studies and patient data. We
identified ß-estradiol and MAPK/ERK as having functional
cross-talk with MYCN and being novel targetable
vulnerabilities of MYCN-amplified neuroblastoma. These
results reveal surprising differences between the
functioning of endogenous, overexpressed and amplified
MYCN, and rationalise how different MYCN dosages can
orchestrate cell fate decisions and cancerous outcomes.
Importantly, this work describes a systems-level approach
to systematically uncovering network based
vulnerabilities and therapeutic targets for
multifactorial diseases by integrating disparate omic
data types.
AB - Despite intensive study, many mysteries remain about the
MYCN oncogene's functions. Here we focus on MYCN's role
in neuroblastoma, the most common extracranial childhood
cancer. MYCN gene amplification occurs in 20% of cases,
but other recurrent somatic mutations are rare. This
scarcity of tractable targets has hampered efforts to
develop new therapeutic options. We employed a multilevel
omics approach to examine MYCN functioning and identify
novel therapeutic targets for this largely un-druggable
oncogene. We used systems medicine based computational
network reconstruction and analysis to integrate a range
of omic techniques: Sequencing-based transcriptomics,
genome-wide chromatin immunoprecipitation, siRNA
screening and interaction proteomics, revealing that MYCN
controls highly connected networks, with MYCN primarily
supressing the activity of network components. MYCN's
oncogenic functions are likely independent of its
classical heterodimerisation partner, MAX. In particular,
MYCN controls its own protein interaction network by
transcriptionally regulating its binding partners. Our
network-based approach identified vulnerable
therapeutically targetable nodes that function as
critical regulators or effectors of MYCN in
neuroblastoma. These were validated by siRNA knockdown
screens, functional studies and patient data. We
identified ß-estradiol and MAPK/ERK as having functional
cross-talk with MYCN and being novel targetable
vulnerabilities of MYCN-amplified neuroblastoma. These
results reveal surprising differences between the
functioning of endogenous, overexpressed and amplified
MYCN, and rationalise how different MYCN dosages can
orchestrate cell fate decisions and cancerous outcomes.
Importantly, this work describes a systems-level approach
to systematically uncovering network based
vulnerabilities and therapeutic targets for
multifactorial diseases by integrating disparate omic
data types.
KW - 4sU-seq
KW - MRNA sequencing
KW - mRNA-seq
KW - MYC
KW - c-MYC
KW - neuroblastoma
KW - transcriptional regulation
U2 - 10.18632/oncotarget.6568
DO - 10.18632/oncotarget.6568
M3 - Article
SN - 1949-2553
VL - 6
SP - 43182
EP - 43201
JO - Oncotarget
JF - Oncotarget
IS - 41
ER -